Evercare, one of the nation's, and Arizona's, largest health care coordination
Thursday, October 25, 2007
Wednesday, October 24, 2007
Saturday, August 25, 2007
The Validation Breakthrough: Simple Techniques for Communicating with People with Alzheimer's Type Dementia
You might get the impression from the title that this book is only for professionals; this is not the case. The validation theory works and it is simple to apply. The case studies are invaluable and provide you with specific situations that you are sure to encounter. I am convinced everyone involved with elderly parents suffering from dementia or Alzheimer's will benefit greatly from this book.
I give The Validation Breakthrough five stars and put it on my must read list. You will certainly reduce stress by learning these techniques.
Please take a moment to read the reviews on the next page.
By Martine Davis
If you live with or care for someone with Alzheimer's or other age related dementia, you must read this book ! What an eye-opener! For the first time I finally understood why Alzheimer's patient say what they say and do what they do. It all makes so much sense now. This small book reads quickly and is full of examples of real people who have been helped with the author's techniques. It shows you how to handle the blaming, accusing, name-calling and the repetitive motions ... It also explains why the way most of us react to Alzheimer's patients actions actually worsens the situation and can cause them to progress to a more advanced stage of Alzheimer's disease ! This book could extend the relationship between the patient and caregivers and should be MANDATORY reading for all staff working in nursing homes and long-term care facilities !
By J. Summers, CNA (Alaska)
An excellent book for both the professional caregiver and families trying to deal with this sometimes unfathomable disease. Gives practical ideas and techniques for helping people with dementia deal with issues from paranoia and blaming to sadness and helplessness. I have just begun to explore these techniques and am finding they work so well that they should be mandatory training for nurses, PCAs and CNAs. Instead of treating our seniors like they are children we at last have a way to talk to them on an adult level, tap into where they are at, deal with the problem at hand and we all come out better for the experience.
Reviewer: A reader
More and more relevant as we care for aging parents. With a title like this one might think: "Boring" Absolutely not so! Right from the start, the stories of the people are so real and so touching that one of my friends said she was moved to tears. She was so sad not to have known about this way of relating to her father. "It works," she told me. "Validation Breakthrough" shows a new way of relating to people with dementia of Alzheimer's type. This approach is effective in helping the person to clear up unresolved issues in their lives. You do not have to be a professionally trained therapist to use validation. Validation will make the relationship more rewarding for both people. It is not hard to learn and makes wonderful sense. Some readers may want to ask new questions of care facilities (like nursing homes) as the validation approach will keep loved ones from slipping into a vegetative state. It will also make the care much kinder, and more rewarding for the care givers
Friday, August 10, 2007
Read more at the Alzheimer's Reading Room: Newly Discovered Antibody May Be Body's Natural Defense Against Alzheimer's (Gammagard)
Monday, August 06, 2007
Source Milton S. Hershey Medical Center
What is it?
Alzheimer's disease is the most common cause of a condition called dementia. Dementia is a general decline in mental ability, such as memory, language skills, judgment, and concentration. Alzheimer’s is a progressive disease, which means symptoms occur gradually and become worse over time. It is named for the German doctor who first described it, Alois Alzheimer.
Who gets it?
Alzheimer’s disease affects most commonly affects those over the age of 65, although it has been diagnosed in people in their 40s and 50s.
What causes it?
The degeneration of parts of the brain, which destroys brain cells, causes the symptoms of Alzheimer’s. However, at this time researchers are not sure what causes this degeneration. Those with a family history of Alzheimer’s are more likely to develop the disease as they age, so there is a gene abnormality that causes the disease in some people. Researchers are looking for links between Alzheimer’s disease and the environment, lifestyle, nutrition, and viruses.
What are the symptoms?
Alzheimer’s usually progresses in three stages, with each lasting anywhere from one to several years. The first symptom of Alzheimer’s disease is usually mild forgetfulness. Someone in the early stages may find him or herself unable to find the right word, recall where something was placed, or recall someone’s name. It may be difficult to concentrate. At this point, symptoms are so general that they do not signal a serious problem or have a great impact on day-to-day functioning. As the disease progresses to the second stage, the forgetfulness becomes worse, making it difficult to function at work, remember directions, or to even make it through the day without difficulty. The person may be restless and unable to sleep at night. His or her personality may change considerably, with increasing anxiety and decreasing emotions. By the late stages of Alzheimer’s, patients suffer from extreme confusion and memory loss. They are unable to recall the names of close friends and family or recent events, and cannot function socially or perform basic daily personal care. Late-stage Alzheimer’s patients may have hallucinations and delusions.
How is it diagnosed?
Alzheimer’s disease is diagnosed by taking a complete medical history and performing a thorough physical examination. Alzheimer’s is generally suspected when there is a gradual deterioration in mental ability. The doctor will perform tests, such as blood tests and brain scans, to rule out other possible causes of the symptoms. The doctor will also ask the patient a series of questions to test his or her mental status. One type of test of mental status is called neuropsychological testing, which is a standardized test of memory, concentration, and visual-spatial skills. Because a definite diagnosis can only be made by performing an autopsy after death, patients are diagnosed with “probable” Alzheimer’s. An autopsy of brain tissue, however, will show areas of abnormal tissue, called plaques, made up of abnormal proteins; a loss of nerve cells; and areas of tangles in the nerve cells that remain in patient’s with Alzheimer’s disease.
What is the treatment?
At this time, there is no cure for Alzheimer’s disease. Treatment focuses on maintaining the best possible quality of life for the patient by providing a supportive environment. Memory aids, such as calendars and other daily reminders of time and place, can help the patient feel more secure and reduce confusion. There are some medications that, when used in the early stages of this disease, can slow memory loss in some patients for a limited amount of time. However, these drugs are used with caution because of potential side effects. Other drugs may be prescribed to treat anxiety, sleeplessness, depression, and hallucinations, as necessary. In the early stages of Alzheimer’s, it is important to help the patient maintain as much independence as possible. As the disease progresses, it may be necessary to seek the help of a home healthcare aid, an adult daycare, or nursing home. While there is currently no treatment to prevent or stop the progression of Alzheimer’s, researchers are continuing to study this disease and test new drugs. There is a possibility that certain types of nonsteroidal anti-inflammatory drugs (NSAIDs) may slow the progression of Alzheimer’s.
A diagnosis of probable Alzheimer’s is devastating for someone who has been accustomed to living an independent life. It is important to provide the patient with emotional and physical support as he or she adjusts to living with this disease. Keeping the daily routine consistent and as stress free as possible is helpful. Because depression is so common in the early stages of Alzheimer’s, you should be aware of the signs of depression and seek help for the patient as soon as possible. Caring for someone with Alzheimer’s can be demanding and discouraging, especially when the loved one does not remember who you are. Your doctor or local social services agency can direct you to support services to help make this time a little easier. Also seek legal advice so it is clear who has the power to make medical and financial decisions once your loved one is no longer able to do this for him or herself. If you have a family history of Alzheimer’s disease, see your doctor for regular checkups. An early diagnosis is important, especially as the medical community learns more about this disease and its treatment. While there is no way to prevent this disease, you can lower your risk and protect yourself from many illnesses by following a healthy diet that is high in fiber and antioxidants and low in saturated fat, and participating in regular physical exercise. Performing activities that stimulate your brain on a regular basis, such as crossword puzzles, word searches, or memory games, may also help maintain mental ability longer.
This information has been designed as a comprehensive and quick reference guide written by our health care reviewers. The health information written by our authors is intended to be a supplement to the care provided by your physician. It is not intended nor implied to be a substitute for professional medical advice.
"early signs of Dementia", early signs of alzheimer's, early signs of alzheimers, early signs of Dementia, milton s hershey medical center, what causes it?, what is it?, who gets it?
Sunday, July 29, 2007
On a personal note, I can tell you my mother is reacts very positively to children. A child always brings a smile to my mothers face. If you look closely you can see she is experiencing real feelings of joy and happiness. On those days where my mother has interactions with children or young adults she usually has a better, brighter day.
Source Sioux City Journal
The generations appear to mesh seamlessly when kids from Building Futures Child Care, a public program of the Boys & Girls Home, make their weekly visit to the Alzheimer's Association's Adult Day Services room.
Without being told, the youngsters eagerly fill in the couple of empty chairs at each table. The clients who came Thursday have been chatting, listening to music or just sitting. Soon, the children's teacher, Julie Bell, and aide Cindy Levering, are passing out clear plastic suncatchers and squeezing splats of bright-colored paints into trays for each person.
The children, ages 4 to 10, have come for an hour or two every Thursday this summer. They play board games, read a library book or do a craft and then share a snack with the clients. Both generations benefit from their time together, even if not everyone remembers it well.
'I love it'
"My middle name is Mess-up," client Marian Persinger laughed as she fixed a drip on her suncatcher. She said she enjoys the children's visits. "The camaraderie. Whatever (craft) they bring, we do. We frosted cookies with them last week," she remembered.
"I know. We made caterpillars," Dylan Thompson, 5, offered. It's not clear whether he meant last week or another time. It doesn't matter.
"Oh, I love it," client Kay Erskine said. "Seeing these kids and watching them, it's really neat."
The children provide a flashback to a happy time for Linda Young, as well. She has attended the center nearly every day for the past three years, since suffering a brain injury in a fall at work.
"It's my first time. I'll watch," said one man who actually comes to the center five days a week. Matt Elgert, 6, unperturbed by the disconnect, painted his suncatcher and talked about playing Candy Land on an earlier visit.
Client Mike Biderman, a retired Navy man who comes to the center often, said he thinks the interaction is good for the children, too. "They should have some exposure to adult life as early as possible," he said.
'Bring somebody joy'
Mary Jo Sikkema, director of the Alzheimer's Association, said the children's visits are important. They keep clients busy, stimulate their brains and give them an opportunity to socialize with other people. She said it's rare that a client doesn't want to participate, or gets agitated.
Stephanie Altamimi, director of Day Services, said she think the clients especially like doing crafts with the children because they feel they are helping the kids. And, she said, the adults feel a connection to all children who visit the center, whether it's the day care children or a family member's child.
Levering said she was surprised at first at how well the children handle their visits. "They're so patient with the clients," she said.
Bell added, "I explained to them they're volunteering their time to bring somebody joy. They really got the concept."
Altamimi said other young people also visit the Day Center. She said sometimes a church or high school group will come and stay most of the day. Some have played band instruments, or drummed up a game of chair volleyball with clients. "We don't ever turn anybody away," she said.
Bell said her group plans to keep its visits going, even after summer ends. They'll come to the center on all the "early out" Mondays of the school year. Days when classes end at 1 p.m., the kids in her program will assemble at the Alzheimer's Day Services Center for crafts, snacks -- and bringing joy.
The 36-Hour Day: A Family Guide to Caring for People with Alzheimer Disease and Memory Loss in Later Life
Thursday, July 26, 2007
The article on the next page is one of the best I have read. The basic underlying premise is that behavior changes slowly in the elderly and if they begin to suffer cognitive impairment it will be evidenced in behavioral changes. Sometimes these changes can be quite subtle but if detected could raise a “red flag”.
If my mother had been enrolled in any of these studies I feel certain she would have been diagnosed with dementia sooner. This would have allowed me to get her in an exercise program, get her proper nutrition, and insure that she was taking her medicines as prescribed. I leaned in the last three years how important these three factors are in the quality of her life.
My mother turned 91 years old in June and she suffers from Alzheimer’s disease. I am her CarGiver.
I am an Alzheimer's Caregiver: The early signs of Dementia (Alzheimer's)
Saturday, July 21, 2007
"The strength of reduction of incidence of dementia with simvastatin is striking,".
Researchers from Boston University School of Medicine (BUSM) have found that the statin, simvastatin, reduces the incidence of Alzheimer’s disease and Parkinson’s disease by almost 50 percent. This is the first study to suggest that statins might reduce the incidence of Parkinson’s disease. These findings, will be published in the July online open access journal BioMed Central (BMC) Medicine.
Statins that stave off Alzheimer's
By Nicole Laskowski
Statins May Stave Off Alzheimer’s
If you’re taking a statin to reduce cholesterol, you may also be improving your chances of avoiding certain neurodegenerative diseases. New research from the School of Medicine indicates that simvastatin, a statin sold as Zocor, reduces the incidence of Alzheimer’s disease and Parkinson’s disease by almost 50 percent.
The researchers, led by Benjamin Wolozin, a MED professor of pharmacology, screened the Decision Support System database of the United States Veterans Affairs Medical System, looking for the effects of three statins — simvastatin, lovastatin, and atorvastatin — on the expected incidence of Alzheimer’s disease and Parkinson’s disease. His study of more than 700,000 subjects taking simvastatin showed that the drug reduced the incidence of both Alzheimer’s disease and Parkinson’s disease by almost 50 percent. A study of people taking atorvastatin showed that the drug reduced the incidence of Alzheimer’s disease by almost 10 percent. Lovastatin was not shown to reduce the incidence of either disease.
Wolozin is unsure why simvastatin reduces the incidence of these diseases, but he suspects that because the statin blocks a cholesterol-producing enzyme called HMG-CoA reductase, it may also affect the production of other chemicals. He notes that simvastatin reduces inflammation, and that it increases the production of some growth factors in the brain, which may make neurons more capable of resisting chronic degenerative disease.
What it means to you:
“If you are someone who is at risk for Alzheimer’s or Parkinson’s disease, you should use simvastatin because it could slow the process,” said Wolozin. “Most people currently use atorvastatin, because it is effective at reducing vascular injury related to cardiovascular disease. If your major health risk is cardiovascular disease, you might want to stay with atorvastatin, but if your major health risk is neurodegenerative disease, you might consider switching to simvastatin.”
Word to the wise:
At the moment, researchers recognize a relationship between simvastatin and the onset of Alzheimer’s and Parkinson’s disease. They do not know how this relationship works. Be advised that statins may cause side effects such as headaches, nausea, rash, weakness, and muscle pain.
What’s next: Wolozin hopes to learn to determine how strong the relationship is between statins and degenerative diseases, like Alzheimer’s and Parkinson’s disease. He plans on studying how the drug slows the progression of symptoms by gathering data on when Alzheimer’s and Parkinson’s disease patients, both on and off the drug, meet certain well-known markers of the diseases.
alzheimer's disease, BioMed Central (BMC) Medicine, Boston University School of Medicine, caregiving, dementia, HMG-CoA reductase, lovastatin, simvastatin, statin, zocor
Tuesday, July 10, 2007
Exelon Patch preferred by caregivers in a study because it helps manage patient care and gives visual reassurance that medication has been administered.
Exelon Patch minimizes gastrointestinal side effects seen with oral form of drug.
Taken directly from the Novartis Press Release
Exelon®Patch, the first and only skin patch for the treatment of Alzheimer's disease, receives first worldwide approval in US
Once-daily skin patch offers novel approach to treating mild to moderate Alzheimer's disease, providing smooth and continuous delivery of drug over 24 hours
Similar efficacy to highest doses of Exelon capsules with significant improvement in memory and ability to perform everyday activities compared to placebo
Exelon Patch preferred by caregivers in a study because it helps manage patient care and gives visual reassurance that medication has been administered
Exelon Patch minimizes gastrointestinal side effects seen with oral form of drug
Basel, July 9, 2007 - Exelon®Patch (rivastigmine transdermal system) has received its first worldwide approval in the United States as an innovative way to deliver an effective medicine for mild to moderate Alzheimer's disease patients through a skin patch instead of an oral capsule.
This new therapy is the first and only transdermal treatment for this degenerative condition affecting millions of people in the US. Exelon Patch offers effective treatment based on placebo-controlled clinical trial results showing significant benefits to patients in terms of their memory and ability to perform everyday tasks as well as helping their overall functioning.
Exelon Patch maintains steady drug levels in the bloodstream, improving tolerability and allowing a higher proportion of patients to receive therapeutic doses of medication, with potential improvements in efficacy. It is applied to the back, chest or upper arm, and provides smooth and continuous delivery of medication through the skin over 24 hours.
Gastrointestinal side effects are commonly seen with this class of drugs called cholinesterase inhibitors. The target dose of Exelon Patch greatly reduces these side effects, with three times fewer reports of nausea and vomiting than with the capsule form of the drug.
"Exelon Patch represents a significant advance in the treatment of this debilitating disease," said George Grossberg, MD, at St. Louis University in St. Louis, Missouri. "The unique delivery system helps both the patient and the caregiver by providing a much easier way to manage their therapy. The patch provides a visual reassurance for the caregiver that the patient is receiving their medication and helps the patient stay engaged in the activities of daily living."
Exelon Patch is expected to be available in US pharmacies soon. The medication was submitted for review in the European Union in late 2006.
The patch was designed with compliance in mind, and was preferred to capsules by more than 70% of caregivers as a method of drug delivery according to clinical study data, because it helped them follow the treatment schedule, interfered less with their daily life and was easier to use overall than the oral medication.
The approval of Exelon Patch is based on results from the international IDEAL (Investigation of Transdermal Exelon in ALzheimer's disease) clinical trial, involving nearly 1,200 patients with mild to moderate Alzheimer's disease. Exelon Patch showed similar efficacy to the highest doses of Exelon capsules1 and the target dose (9.5 mg/24 hours) was well tolerated by patients.
"Innovation isn't just about developing new compounds, but also about meeting therapeutic needs by taking existing knowledge and applying it in new ways," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Exelon Patch addresses an important medical need by delivering a proven drug in an entirely new form that meets the needs of patients and their caregivers."
Alzheimer's disease is a progressive, degenerative disease that alters the brain, causing impaired memory, thinking and behavior. Approximately 18 million people worldwide have Alzheimer's disease. In the US, more than five million people suffer from Alzheimer's disease and almost 10 million people provide care for someone living with dementia, most of which is related to Alzheimer's disease. By 2030, the number of people in the US who are age 65 and over with Alzheimer's disease is estimated to reach 7.7 million, more than 50% more than current levels.
The FDA also approved the use of Exelon Patch in treating patients with mild to moderate Parkinson's disease dementia. Parkinson's disease is a chronic and progressive neurological condition that affects approximately 1.5 million people in the US. Parkinson's disease dementia is a distinct and common disorder, one characterized by impairments in executive function, memory retrieval, and attention, in patients with an established diagnosis of Parkinson's disease. Two of five people with Parkinson's disease are estimated to have Parkinson's disease dementia.
The foregoing press release contains forward-looking statements that can be identified by forward-looking terminology, such as "expected to be", or implied statements regarding potential future revenues from the Exelon Patch. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. There can be no guarantee that Exelon Patch will reach any particular sales levels. In particular, management's expectation regarding the commercial success of Exelon Patch could be affected by among other things, uncertainties relating to product development, regulatory actions or delays or government regulation generally, the ability to obtain or maintain patent or other proprietary intellectual property protection and competition in general, as well as factors discussed in the Form 20F filed with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
# # #
Novartis Media Relations
Novartis Global Media Relations
+41 61 324 9577 (direct)
+41 79 248 5717 (mobile)
email@example.com Christine Cascio
Novartis Pharma Communications
+1 862 778 8026 (direct)
+1 917 449 9982 (mobile)
alzheimer's disease, caregiver, Exelon Patch, family caregiver, novartis, skin patch, worldwide approval
Tuesday, July 03, 2007
How often older adults read a newspaper, play chess, or engage in other mentally stimulating activities is related to the risk of developing Alzheimer’s disease, according to a study by researchers at Rush University Medical Center.
Taken directly from the Rush Memory and Aging Project news release.
Frequent Brain Stimulation in Old Age Reduces Risk of Alzheimer’s Disease
(CHICAGO) – How often older adults read a newspaper, play chess, or engage in other mentally stimulating activities is related to the risk of developing Alzheimer’s disease, according to a study by researchers at Rush University Medical Center published June 27 in the online edition of Neurology®, the medical journal of the American Academy of Neurology.
For the study, more than 700 people in Chicago with an average age of 80 underwent yearly cognitive testing for up to five years. Participants were part of the Rush Memory and Aging Project, a longitudinal study of more than 1,200 older people. Of the participants, 90 developed Alzheimer’s disease. Researchers also performed a brain autopsy on the 102 participants who died.
The study found that a cognitively active person in old age was 2.6 times less likely to develop dementia and Alzheimer’s disease than a cognitively inactive person in old age. This association remained after controlling for past cognitive activity, lifetime socioeconomic status, and current social and physical activity.
Researchers say the findings may be used to help prevent Alzheimer’s disease.
“Alzheimer’s disease is among the most feared consequences of old age,” said study author Robert S. Wilson, PhD, a neuropsychologist at the Rush Alzheimer’s Disease Center. “The enormous public health problems posed by the disease are expected to increase during the coming decades as the proportion of old people in the United States increases. This underscores the urgent need for strategies to prevent the disease or delay its onset.”
Wilson says the study also found frequent cognitive activity during old age such as visiting a library or attending a play, was associated with reduced risk of mild cognitive impairment, a transitional stage between normal aging and dementia, and less rapid decline in cognitive function.
The study was supported by grants from the National Institute on Aging and the Illinois Department of Public Health.
The Rush Alzheimer's Disease Center is one of 29 NIA-supported Alzheimer's Disease Centers across the U.S. which conduct basic science, clinical, and social and behavioral research on dementia and AD. General information on aging and aging research can be viewed at the NIA's home website, www.nia.nih.gov. For more information on the Rush Alzheimer’s Disease Center, visit www.rush.edu.
"ACTIONALZ.ORG", alzheimer's disease, blog, brain, stimulation, caregiver, care giving, chess, mental-health, National Institute on Aging, neurology, prevent, Rush University Medical Center
Tuesday, June 26, 2007
This study is currently recruiting patients.
Personal Note: I have been feeding my mother fish and giving her Omega 3 Oil daily for a couple of years. I believe it is beneficial.
For a complete description of the trial including eligibility requirements go to the Clinical Trials Page
Official Title: A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer’s Disease
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Further study details as provided by National Institute on Aging (NIA)
Primary Outcome Measures:
Changes in rate of cognitive and functional decline measured by ADAS-Cog and CDR-SOB
Preliminary studies have shown a reduced risk of Alzheimer's disease (AD) in people consuming increased amounts of fish in their diets. Many of the health benefits of fish are attributed to the abundance of omega 3 fatty acids. Docosahexaenoic Acid (DHA) is the most abundant omega 3 fatty acid in the brain. Data from several animal models supports the hypothesis that DHA may be an effective treatment for AD by means of anti-amyloid, antioxidant, and neuroprotectant mechanisms.
In this study, 400 individuals with mild to moderate AD will participate at approximately 53 study sites throughout the US for 18 months. Participants will be randomized so that 60% will receive approximately 2 grams of DHA, divided into 4 capsules, 2 capsules taken twice a day, while 40% receive an identical placebo.
Potential participants will go to their study site for a screening visit, where eligibility is determined, and if accepted, for a baseline visit where cognitive status, behavioral status, functional status, and global severity of dementia will be assessed. Vital signs and biomarker labs will also be obtained. Subsequent visits will occur every three months for medication checks and, every 6 months, further assessments, physical exams, and labs.
Some participants will also take part in MRI (magnetic resonance imaging) and/or CSF (cerebrospinal fluid) sub-studies. For the MRI sub-study, scans will be done prior to beginning the study medication, and again after 18 months. Likewise, for the CSF sub-study, a lumbar puncture will be done prior to beginning the study medication, and again after 18 months.
Enrollment is restricted to individuals who consume no more than 200 mg of DHA per day, which is almost 300% of the average daily intake in an American diet. Individuals who take fish oil or omega 3 fatty acid supplements are also not eligible. Each visit will include completion of a very brief food frequency questionnaire to monitor dietary DHA levels.
Tuesday, June 19, 2007
The goal of REVEAL is to provide healthy adults with genetic susceptibility testing and information about their chances to develop Alzheimer's disease.
Genetics and Alzheimer's Risk
More at the Alzheimer's Reading Room,
Saturday, June 16, 2007
Wednesday, May 09, 2007
The 36-Hour Day: A Family Guide to Caring for People with Alzheimer Disease, Other Dementias, and Memory Loss in Later Life
This best-selling book is the "bible" for families caring for people with Alzheimer disease...
Read the full text review at The Alzheimer's Reading Room
Monday, April 09, 2007
From the Alzheimer's Reading Room : Americans Fear Alzheimer’s More Than Heart Disease, Diabetes or Stroke
Friday, March 23, 2007
Read this article in its entirety at The Alzheimer's Reading Room
Thursday, March 22, 2007
A simple fruit smoothie could soon help improve thinking and memory in Alzheimer's patients.
Fruit Smoothie Could Improve Thinking, Memory In Alzheimer's Patients
St. Louis University is the only U.S test center to study whether the drink actually works. The beverage isn't a new drug, but a nutritional drink with a combination of vitamins, antioxidants and lipids that are consumed once a day. The smoothie comes in peach or cappuccino flavors.
Dr. Theodore Malmstrom is one of three researchers looking into what could soon be a very important weapon in the fight against Alzheimer's.
"There is increasing evidence that concentrated components of natural foods can improve memory so those components have been put in a drink and we are hopeful it will help," said Malmstrom.
The goal now is to get actual patients to test it out.
SLU researchers need at least 10 Alzheimer's patients to take part in the study. They are looking for people recently diagnosed with Alzheimer's, but not currently taking medications.
Patients will be divided in two groups. One group will get a daily supply of drinks with nutritional supplements. The other group will get a similar drink but without the nutritional additions.
Results of the 24-week study will hopefully end with good news.
"There is always great hope whenever you can have new research emerging. One of the Alzheimer's Associations mission (is) to fund research programs so we are very excited," said Stephanie Rohlfs-Young, the outreach director for the St. Louis Chapter of the Alzheimer's Association.
The risk of side effects from the drink are very minor compared to side effects from the five FDA-approved medications that treat Alzheimer's.
For more information, contact Malmstrom at 314-577-8745.
Tuesday, March 20, 2007
Someone Develops Alzheimer's Every 72 Seconds, According To New Alzheimer's Association Report.
The Alzheimer’s Association today reports that in 2007 there are now more than 5 million people in the United States living with Alzheimer’s disease. This number includes 4.9 million people over the age of 65 and between 200,000 and 500,000 people under age 65 with early onset Alzheimer’s disease and other dementias.
Read More About Alzheimer's
A Simple Three Minute Test Can Detect the Earliest Stage of Alzheimer's disease
High cholesterol levels in your 40s raises Alzheimer's risk
Alzheimer's Disease Genetics Fact Sheet
Ten Million Baby Boomers likely to suffer from Alzheimer’s during their lifetime
Thursday, March 15, 2007
About a third of those who take care of loved ones with the disease feel 'more religious' because of their experiences, a new national study says.
You can read this article at The CareGiver Weblog
Wednesday, March 14, 2007
Dr. Robert S. Wilson told Reuters Health that difficulty identifying odors seems to be related the buildup of 'tangles' in the brain that appear early in the development of Alzheimer’s disease. “We found the correlation of difficulty identifying familiar odors with Alzheimer’s disease pathology even in people without dementia,” he added.
Go read the entire article at The Alzheimer's Reading Room Weblog: Trouble identifying odors points to Alzheimer’s
Sunday, March 11, 2007
CareGiver: The Book: What Happened to the Italian Bread?
Thursday, March 08, 2007
"Nursing home residents with Alzheimer's disease who participate in a moderate exercise program have a significantly slower deterioration than those who receive routine medical care, researchers have shown."
Read the article in its entirety at the CareGiver: The Book Weblog
"Nursing home residents with Alzheimer's disease who participate in a moderate exercise program have a significantly slower deterioration than those who receive routine medical care, researchers have shown."
Read the article in its entirety at the CareGiver: The Book Weblog
Sunday, February 04, 2007
Read about the study including requirements and available locations at The Alzheimer's Reading Room: Huperzine A in Alzheimer's Disease-The Clinical Trial.
Sunday, January 21, 2007
Read this article in its entirety Alzheimer's: Understand and control wandering.
Wednesday, January 03, 2007
From CareGiver: The Book
I can still remember the day. An experience that told me: you are not alone; it’s all about the disease. An experience that let me know I could learn from the experience of others that came before me. That it would be possible for me to get ahead of the curve and get “mentally” prepared.
In the beginning one of the things that drove me crazy was my mother’s constant eating. My mother would just eat and eat and eat. Even though she was overeating she would tell her friends on the telephone that she had not eaten a thing all day. And, this was at 4:30 in the afternoon. It seemed that the more she ate the more she denied eating. And it only continued to get crazier and crazier. My mother who was a good 30 pounds overweight told her friends I was trying to starve her. The friends believed her. They called me in the background to ask me why I wasn’t feeding my mother. They couldn’t accept she was suffering from Alzheimer’s disease so they believed her. When I asked them if it looked like she was being starved they just did not know how to respond. They just got confused. They knew then it wasn’t true.
It might not be easy to envision this but my mother could eat a five course meal and then turn around and eat again in 30 minutes. This happened for the first time on Easter Sunday. We went to a buffet style brunch at the Delray Country Club. My mother had everything that day ranging from a ham and cheese omelet, to a slice of prime rib, turkey, potatoes, and even a couple of desserts. When we arrived home she changed her cloths and ate a large bowl of cereal with a banana. I had been thinking to myself that I was going to be unable to eat anything for the rest of the day. Seeing her eating the cereal drove me crazy, literally up the wall. This was becoming a common experience for me. It left me angry, confused and completely out of sorts. I just wanted to scream, Stop!
I am not talking about a gigantic woman. Before the Alzheimer’s really started taking hold, I doubt her weight fluctuated more than five to seven pounds over the previous 15 years. She wore a size 6-8 all those years.
Now, it was not unusual for my mother to eat at 11:30 at night, to get up out of bed and eat at 1:30 in the morning and 4.27 AM. She would eat breakfast at 7 AM and again at 9. She would eat lunch, several snacks, and everyday at 4:30 in the afternoon shortly after I reminded her that we would be eating dinner in half an hour--a sandwich. You could set your clock to the time of day. I could go out into the kitchen and just wait for her or better yet just perk my ears up at 4:30 and listen for the refrigerator to start beeping. Later she would have dinner and begin the cycle all over again beginning around 9 o’clock at night.
This pattern of eating was driving me crazier and crazier. My tiny 5 foot tall mother had ballooned to 152 pounds. I knew this was dangerous to her health (she was developing visceral fat and this can be life threatening). She could barely walk to the mailbox and back. It was causing her to become more and more sedentary. It was a vicious cycle. I didn’t know what to do or where to turn.
Finally, I decided to get us into the gym for some exercise (my own weight had ballooned all the way up to 206). As I was thinking about how I might accomplish this mission we received a flyer in the mail from my mother’s healthcare provider (Humana). It was almost as if I was receiving an answer to a prayer: the Silver Sneakers Program. The flyer announced that on January 1, 2005 all Humana Gold Plus members would be eligible for a free membership to a gym and enrollment into a exercise program specifically designed for Senior citizens. I enrolled my mother into the Silver Sneakers Program (SSP) and bought myself a two year membership to Gold’s Gym in Delray Beach. Since the SSP was offered at Gold’s this allowed us to go to the gym and to work out at the same time. And this is where it happened.
Next time Part 2. Some startling realizations, the end of denial, the beginning of an understanding of the behavior around the disease, and my own mental construct of how to deal emotionally with the behavior.